Clinical and Molecular Hepatology

Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations: Sherlot Juan Song, Eileen Laureal Yoon, Vincent Wai-Sun Wong, Ae Jeong Jo, Grace Lai-Hung Wong, Jimmy Che-To Lai, Dae Won Jun, Terry Cheuk-Fung Yip; Received July 28, 2025 Accepted December 9, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3350/cmh.2025.0851 [Accepted]

Abstract
PDF

Background & Aims
Previous studies have identified a substantial degree of agreement between the non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) populations, but the same notion may not apply to normal-weight patients with a lower cardiometabolic risk burden. This study aims to investigate the CMRF distributions between normal-weight and overweight/obese MASLD, the agreement between historical NAFLD and MASLD, and to compare the risk of liver-related events (LREs) and all-cause mortality in normal-weight versus overweight or obese MASLD.
Methods
This study included participants with steatotic liver disease (SLD) from five cohorts in Hong Kong, South Korea, and the United States. Participants were recruited from settings including both hospitals and communities. Individuals were classified into normal-weight and overweight/obese groups.
Results
This study included 33,793 participants with SLD from five cohorts, of whom 20,893 and 20,701 patients met the diagnosis of NAFLD and MASLD, respectively. Normal-weight patients with NAFLD demonstrated a lower CMRF distribution compared to those with overweight/obese NAFLD. In the community-based cohorts, the proportions of 0 CMRF ranged from 9.0-26.7% among normal-weight NAFLD, representing the discrepancy between MASLD and NAFLD definitions. Compared with the overweight/obese MASLD, the normal-weight MASLD had increased all-cause mortality (normal-weight vs. overweight/obese, 23.44 and 13.80 per 1000 person-years; p<0.001) but not LREs (2.81 and 2.59 per 1000 person-years; p=0.54) in the HK CDARS cohort.
Conclusions
Normal-weight individuals with NAFLD demonstrated a lower distribution of CMRFs, resulting in the incomplete agreement between historical NAFLD and MASLD.
Ethical Compliance
For all involved cohorts, the study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the appropriate clinical research ethics committee and/or institutional review board, which provided either written consent or a waiver of informed consent.

117 View
11 Download

Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurement: Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip; Received August 6, 2025 Accepted November 2, 2025 Published online November 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0888 [Accepted]

Abstract
PDF

Background/Aims
Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using FIB-4 followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography. However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.
Methods
This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.
Results
F3-F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.2) and high-FIB-4-high-LSM (aSHR 21.3) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.
Conclusions
Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.

824 View
110 Download

Correspondence to the editorial “ASB3 degrades the gateway to β-oxidation: on Hepatocytic ASB3 deficiency alleviates MASLD by decreasing ubiquitin-mediated CPT1A”: Dongqin Yang, Yuli Lin, Chunhua Song, Ming Guan; Received September 25, 2025 Accepted September 27, 2025 Published online September 29, 2025; DOI: https://doi.org/10.3350/cmh.2025.1100 [Accepted]

PDF

655 View
45 Download

Correspondence to the editorial on “Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease (CHM-2025-1013)”: Yuli Lin, Dongqin Yang, Zhihao Wu, Ming Guan, Chunhua Song; Received September 23, 2025 Accepted September 27, 2025 Published online September 29, 2025; DOI: https://doi.org/10.3350/cmh.2025.1086 [Accepted]

PDF

548 View
29 Download

Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Yueying Yang, Ying Yang, Yan Lu; Received September 8, 2025 Accepted September 8, 2025 Published online September 15, 2025; DOI: https://doi.org/10.3350/cmh.2025.1013 [Accepted]

PDF

964 View
38 Download

Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation: Lu Jiang, Lan-Duoduo Du, Jing Zeng, Hui-kuan Chu, Zhong Peng, Jian-Gao Fan; Received July 2, 2025 Accepted August 11, 2025 Published online August 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.0718 [Accepted]

Abstract
PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD), formally known as non-alcoholic fatty liver disease, has become the most common form of chronic liver disease in children. The spectrum of pediatric MASLD ranges from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and in rare cases, hepatocellular carcinoma. Its pathogenesis involves a complex interplay among genetic, epigenetic, and environmental factors, along with alterations in the gut microbiota and its associated metabolites. Given the staggering prevalence and the distinct etiopathogenesis of pediatric MASLD, characterization of the gut microbiota and microbial products could facilitate the development of diagnostic tools and inform targeted therapeutic strategies. Current research on the gut microbiome in the context of pediatric MASLD is limited by small sample size, inadequate use of liver biopsy, methodological inconsistencies in sequencing, and confounding effects from metabolic comorbidities. In this review, we summarize clinical studies on alterations in the gut microbiota and microbial products (short-chain fatty acids, bile acids, and ethanol) that impact the pathogenesis of pediatric MASLD. We discuss the therapeutic potential of dietary modification, pharmacological treatments, and probiotics in improving disease progression by summarizing current clinical studies. Enhancing our understanding of the gut-liver axis may aid in the development of effective therapeutic strategies for pediatric MASLD.

3,778 View
161 Download

Comment on “High Steatosis-Associated Fibrosis Estimator Scores Predict Hepatocellular Carcinoma in Viral and Non-Viral Hepatitis and Metabolic Dysfunction-Associated Steatotic Liver Disease”: Prajnasini Satapathy, Rachana Mehta, Ranjana Sah; Received August 2, 2025 Accepted August 6, 2025 Published online August 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0875 [Accepted]

PDF

2,245 View
19 Download

Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A: Yuli Lin, Wulei Hou, Mengxiao Ge, Zhihao Wu, Linlin Huang, Haoye Liu, Wenli Zhang, Xiyu Deng, Lanxin Wang, Ming Guan, Chunhua Song, Zuoyun Wang, Dongqin Yang; Clin Mol Hepatol 2025;31(4):1333-1354.
Published online August 8, 2025; DOI: https://doi.org/10.3350/cmh.2024.1041

Background/Aims
Excessive lipid accumulation in hepatocytes is a critical cause of metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Ankyrin repeat and SOCS box protein 3 (ASB3) is an E3 ubiquitin ligase that mediates diverse disease processes; however, the direct substrates of ASB3 in lipid metabolism and its role in MASLD remain unexplored.
Methods
We generated ASB3 knockout mice fed a high-fat diet to induce MASLD. Oxygen consumption and fatty acid oxidation (FAO) were used to assess lipid metabolism. LC-MS/MS and IP were used to verify the ASB3 target protein. Correlation analysis was conducted on the cohort of MASLD patients vs. the control group.
Results
Loss of the ASB3 E3 ubiquitin ligase in hepatocytes strengthens mitochondrial FAO, thereby influencing energy consumption to decrease triglyceride storage and lipid accumulation. Quantitative lysine ubiquitination proteomics revealed that ASB3 directly mediated the ubiquitin levels at two sites (K180 and K639) in carnitine palmitoyl transferase 1A (CPT1A), a rate-limiting enzyme of FAO, to induce CPT1A degradation. Moreover, both constitutive and hepatocyte-specific ASB3 knockout enhance FAO and delay lipid accumulation, liver steatosis, and MASLD progression in a CPT1A-dependent manner. Hepatic ASB3 deficiency also delays fibrosis in MASLD. Analysis of public databases and liver tissue samples from MASLD patients revealed that ASB3 was highly expressed in MASLD patients and was negatively correlated with CPT1A.
Conclusions
Our study reveals the key roles of ASB3 in the development of MASLD and suggests a novel therapeutic potential for MASLD.

3,872 View
450 Download

GLP-1RA may open a new era for MASLD treatment: Ye Feng, Chengfu Xu; Received June 12, 2025 Accepted June 19, 2025 Published online June 24, 2025; DOI: https://doi.org/10.3350/cmh.2025.0628 [Accepted]

PDF

1,756 View
69 Download

Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”: May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong; Received April 14, 2025 Accepted April 24, 2025 Published online April 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0420 [Epub ahead of print]

PDF

Citations

Citations to this article as recorded by

Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway
Hye Won Lee, Seung Up Kim
Clinical and Molecular Hepatology.2025;[Epub] CrossRef

4,062 View
31 Download
Crossref

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study: Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen; Clin Mol Hepatol 2025;31(3):1084-1099.
Published online April 23, 2025; DOI: https://doi.org/10.3350/cmh.2024.1096

Background/Aims
Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted a target trial emulation study to evaluate whether GLP-1RA decreases the risk of liver and non-liver outcomes.
Methods
Patients with T2D and MASLD initiating GLP-1RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) were included from 2013 to 2022 in Merative™ Marketscan^® Research Databases. Primary outcomes included incidences of (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Inverse probability of treatment weighting was applied to balance baseline characteristics and Cox regression models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI).
Results
In the intention-to-treat design, GLP-1RA, compared with DPP-4i, had a significantly lower incidence (per 1,000 person-years) of HCC (0.8 vs. 1.7; HR 0.53, 95% CI 0.39–0.71), of cirrhosis (29.3 vs. 32.9; HR 0.91, 95% CI 0.86–0.96), of CVD (57.2 vs. 73.9; HR 0.90, 95% CI 0.86–0.95), of CKD (4.5 vs. 6.8; HR 0.73, 95% CI 0.64–0.84), and of non-liver cancer (16.9 vs. 22.9; HR 0.82, 95% CI 0.77–0.89). In the per-protocol design, significant inverse associations for these study outcomes still were observed, with HR 0.60–0.77.
Conclusions
In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.

Citations

Citations to this article as recorded by

Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study
Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai
European Journal of Pharmacology.2025; 1005: 178088. CrossRef
Impaired Thyroid Hormone Sensitivity is Associated with Increased Risk of Liver Fibrosis in Euthyroid Population: A Cross-Sectional Analysis of NHANES
Xingyu Yao, Kaiwen Xiao, Hein Ko Oo
Hormone and Metabolic Research.2025; 57(09): 511. CrossRef

9,992 View
268 Download
3 Web of Science
Crossref

Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Shang-Chin Huang, Jia-Horng Kao; Received April 3, 2025 Accepted April 8, 2025 Published online April 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0369 [Epub ahead of print]

PDF

3,356 View
34 Download

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States: Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang; Clin Mol Hepatol 2025;31(3):1058-1070.
Published online April 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0169

Background/Aims
Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in alcohol-associated liver disease (ALD) and alcohol-attributable cancers in the United States (US) from 2000 to 2021.
Methods
Using the methodological framework of the Global Burden of Disease Study 2021, we analyzed trends in incidence, prevalence, and mortality from ALD and alcohol-attributable cancers in the US.
Results
In 2021, there were 28,340 new cases of ALD, 227,730 prevalent cases, and 21,860 deaths attributed to ALD in the US. From 2000 to 2021, ALD incidence, prevalence, and mortality increased by 43%, 36%, and 79%, respectively. The age-standardized incidence and death rate of ALD rose disproportionately among females compared to males. For alcohol-attributable cancers, primary liver cancer, colorectal cancer, and esophageal cancer accounted for the largest share of deaths in 2021. Age-standardized death rates increased significantly for primary liver cancer (annual percent change [APC] 2.21%, 95% confidence interval [CI] 1.70–2.73%) and other pharyngeal cancer (APC 1.35%, 95% CI 1.08–1.62%).
Conclusions
The burden of ALD is substantial and continues to rise in the US, with a particularly notable increase among females. Mortality from alcohol-attributable cancers is also increasing, mainly driven by primary liver cancer and pharyngeal cancer. However, system-wise, gastrointestinal cancer had the highest death attributable to alcohol. These findings highlight the urgent need for public health strategies to tackle ALD, primary liver cancer, and alcoholattributable extrahepatic malignancies.

Citations

Citations to this article as recorded by

Rising burden of steatotic liver disease in women of childbearing age and projections to 2035
Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
JHEP Reports.2026; 8(1): 101646. CrossRef
MetALD: new insights and unraveling therapeutic potential
Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul
Liver International.2025;[Epub] CrossRef
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado
P. Huerta, J.P. Arab, L.A. Díaz
Revista de Gastroenterología de México.2025; 90(4): 509. CrossRef
Alcohol use and cirrhosis in women: An underestimated risk
P. Huerta, J.P. Arab, L.A. Díaz
Revista de Gastroenterología de México (English Edition).2025; 90(4): 509. CrossRef

9,516 View
147 Download
5 Web of Science
Crossref

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease: Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim; Clin Mol Hepatol 2025;31(3):1018-1031.
Published online April 4, 2025; DOI: https://doi.org/10.3350/cmh.2024.1183

Background/Aims
Recently, the Korean Association for the Study of the Liver (KASL) introduced a noninvasive test-based approach that uses the fibrosis-4 (FIB-4) index followed by vibration-controlled transient elastography (VCTE) to identify high-risk patients with metabolic-associated steatotic liver disease (MASLD). In this study, the KASL two-step approach was validated by assessing the risk of liver-related event (LRE) development.
Methods
We retrospectively analyzed 8,131 patients with MASLD who underwent VCTE between 2012 and 2020. The index date was defined as the date of the VCTE measurement. Using the KASL two-step approach (FIB-4 index and subsequent VCTE), patients were stratified into four groups (low-, intermediate-low-, intermediate-high-, and high-risk groups). Outcomes, including LREs such as decompensation (DCC) or hepatocellular carcinoma (HCC) were evaluated.
Results
During the follow-up (median 46.6 months), 86 (1.1%) patients developed LREs (39 [0.5%] with DCC and 47 [0.6%] with HCC). The KASL two-step approach classified 67.6%, 17.7%, 5.7% and 9.0% of patients in the low-, intermediate-low-, intermediate-high-, and high-risk groups, respectively. The cumulative incidences of LREs increased proportionally according to risk stratification (0.07%, 0.10%, 0.29%, and 1.51% at 3 years and 0.35%, 0.26%, 1.94% and 5.46% at 5 years). The overall accuracy in predicting LREs ranged from 67.7–99.8%. The FIB-4 index and subsequent Agile3+, Agile 4, or FibroScan aspartate aminotransferase scores showed similar predictive abilities compared to the KASL approach.
Conclusions
The KASL two-step approach is an effective and practical method for risk stratification in patients with MASLD, optimizing patient care through early identification of high-risk individuals.

Citations

Citations to this article as recorded by

Validation of combo ichroma as a reliable concentration-based alternative for AST and ALT measurement in liver disease monitoring
Minsoo Kim, Su A Kim, Jeong Min Kim, Hee Young Kim, Ho Yeong Yoon, Sung Won Park, Daegyun Park, Ji Sook Han, Ki Tae Suk
Methods.2025; 243: 66. CrossRef
Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway
Hye Won Lee, Seung Up Kim
Clinical and Molecular Hepatology.2025;[Epub] CrossRef

10,632 View
200 Download
1 Web of Science
Crossref

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment: Hee Yeon Kim, Mary E. Rinella; Clin Mol Hepatol 2025;31(3):753-770.
Published online April 2, 2025; DOI: https://doi.org/10.3350/cmh.2025.0083

Abstract
PDF

Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration’s (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain.

Citations

Citations to this article as recorded by

Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts
Nutrients.2025; 17(13): 2189. CrossRef
Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?
Amedeo Lonardo, Ralf Weiskirchen
Exploration of Drug Science.2025;[Epub] CrossRef
Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH
Yunfan Bai, Jingxin Ju, Ruishi Xie, Jing Li, Xinyi Zhao, Xiaoxue Fang, Ming Zhu, Xintian Lan, Haoming Luo
International Immunopharmacology.2025; 166: 115539. CrossRef
Full Active Nanoplatform Restores ROS Homeostasis for Synergistic Therapy of Fatty Liver Disease via Dual Endogenous–Exogenous Pathways
Ziyi Lin, Peng Xu, Yuehai Xu, Yixin Zheng, Huimin Li, Zixin Chen, Zhe Wang, Shaochen Song, Yuhao Liu, Zhao Yang, Ju Cui, Heyun Shen
ACS Applied Materials & Interfaces.2025;[Epub] CrossRef
Quzhou-sourced Fructus Aurantii ameliorates MASLD by modulating glycolysis-dependent M1 polarization in hepatic macrophages
Junbin Yan, Yunmeng Nie, Menglu Ding, Mi Zhou, Tingyuan Li, Sumei Xu, Shuo Zhang
Phytomedicine.2025; : 157572. CrossRef
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma
Dingwu Li, Xiang Zhang
Hepatology Communications.2025;[Epub] CrossRef

9,799 View
291 Download
4 Web of Science
Crossref

Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”: Sisi Yang, Zhenxuan Ma; Received February 11, 2025 Accepted March 6, 2025 Published online March 7, 2025; DOI: https://doi.org/10.3350/cmh.2025.0153 [Epub ahead of print]

PDF

3,719 View
29 Download

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”: Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou; Clin Mol Hepatol 2025;31(3):e252-e253.
Published online February 26, 2025; DOI: https://doi.org/10.3350/cmh.2025.0189

PDF

6,921 View
75 Download

Steatotic liver disease

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025: Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL); Clin Mol Hepatol 2025;31(Suppl):S1-S31.
Published online February 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.0045

Citations

Citations to this article as recorded by

Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma
Eun Ji Jang, Ho Joong Choi, Young Kyoung You, Deok Hwa Seo, Mi Hyun Kwon, Keungmo Yang, Jaejun Lee, Jeong Won Jang, Seung Kew Yoon, Ji Won Han, Pil Soo Sung
Cancers.2025; 17(9): 1548. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications
Hyo Young Lee, Eileen L. Yoon
The Korean Journal of Gastroenterology.2025; 85(2): 126. CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang
Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee
The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
Nutrients.2025; 17(13): 2211. CrossRef
Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study
Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
Cardiovascular Diabetology.2025;[Epub] CrossRef
Second-line antidiabetic drugs: friend or foe of the liver
Jiwon Yang, Gunho Kim, Ju Hyun Shim, Jihyun An
Journal of Liver Cancer.2025; 25(2): 187. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Jaehyun Bae
The Journal of Korean Diabetes.2025; 26(3): 172. CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
Hepatology Communications.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Ralf Weiskirchen, Amedeo Lonardo
International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis
Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li
European Journal of Medical Research.2025;[Epub] CrossRef
Risk of Esophageal and Gastric Cancer by Histologic Subtype in Steatotic Liver Disease: A UK Biobank Study
Donghoon Kang, Ji Won Han, Kenneth R. Muir, Artitaya Lophatananon, Jongin Lee
Cancers.2025; 17(21): 3416. CrossRef

8,768 View
273 Download
10 Web of Science
Crossref

Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease”: Ho Soo Chun, Minjong Lee; Received February 2, 2025 Accepted February 7, 2025 Published online February 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0116 [Epub ahead of print]

PDF

4,715 View
28 Download

Steatotic liver disease

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”: Jing Zeng, Jian-Gao Fan; Clin Mol Hepatol 2025;31(2):e218-e220.
Published online February 3, 2025; DOI: https://doi.org/10.3350/cmh.2025.0070

PDF

4,585 View
31 Download

What is new in the 2024 Chinese guidelines for fatty liver disease?: Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan; Clin Mol Hepatol 2025;31(3):e239-e246.
Published online January 21, 2025; DOI: https://doi.org/10.3350/cmh.2024.1165

PDF

7,712 View
92 Download

Steatotic liver disease

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”: Seogsong Jeong, Won Kim, Sang Min Park; Clin Mol Hepatol 2025;31(2):e210-e211.
Published online January 6, 2025; DOI: https://doi.org/10.3350/cmh.2024.1175

PDF

5,489 View
35 Download

Steatotic liver disease

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”: Seogsong Jeong, Won Kim, Sang Min Park; Clin Mol Hepatol 2025;31(2):e208-e209.
Published online January 6, 2025; DOI: https://doi.org/10.3350/cmh.2024.1171

PDF

5,612 View
37 Download

Steatotic liver disease

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”: Ji Won Han, Dae Won Jun; Clin Mol Hepatol 2025;31(2):e152-e154.
Published online December 30, 2024; DOI: https://doi.org/10.3350/cmh.2024.1160

PDF

5,344 View
42 Download

Steatotic liver disease

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”: Jing Zeng, Jian-Gao Fan; Clin Mol Hepatol 2025;31(2):610-614.
Published online December 17, 2024; DOI: https://doi.org/10.3350/cmh.2024.1099

PDF

Citations

Citations to this article as recorded by

Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen
Clinical and Molecular Hepatology.2025; 31(2): e173. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Jing Zeng, Jian-Gao Fan
Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef

5,847 View
50 Download
2 Web of Science
Crossref

Hepatic neoplasm

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”: Hai Xu, Yong Zhou, Huikun Wu; Clin Mol Hepatol 2025;31(2):e125-e127.
Published online December 17, 2024; DOI: https://doi.org/10.3350/cmh.2024.1087

PDF

Citations

Citations to this article as recorded by

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clinical and Molecular Hepatology.2025; 31(2): e208. CrossRef

5,648 View
43 Download
Crossref

Steatotic liver disease

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease: Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan; Clin Mol Hepatol 2025;31(Suppl):S94-S111.
Published online November 28, 2024; DOI: https://doi.org/10.3350/cmh.2024.0811

Abstract
PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.

Citations

Citations to this article as recorded by

Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework
Senlin Wang, Ruimin Zhang, Peisen Guo, Huawu Yang, Yanjun Liu, Hongmei Zhu
EPMA Journal.2025; 16(1): 183. CrossRef
Deciphering the role of dietary modifications and gut dysbiosis in Non-Alcoholic Fatty Liver Disease
Meenakshi Vachher, Kohinoor Kaur, Manisha Marothia, Archana Burman, Deepanjana, Savita Bansal
Human Nutrition & Metabolism.2025; 40: 200305. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
Exploration of Medicine.2025;[Epub] CrossRef
Electroacupuncture Attenuates Intestinal Barrier Disruption via the α7nAChR-Mediated HO-1/p38 MAPK/NF-κB Pathway in a Mouse Model of Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized, Single-Blind, Controlled Trial
Xiao Wang, Jiasen Sun, Peng Wang, Yimin Zhang, Jiuyang Chang, Zhijun Duan
Biomedicines.2025; 13(4): 802. CrossRef
Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions
Carolina Jiménez-González, Marta Alonso-Peña, Paula Argos Vélez, Javier Crespo, Paula Iruzubieta
Nutrients.2025; 17(9): 1580. CrossRef
Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies
Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral
Food and Agricultural Immunology.2025;[Epub] CrossRef
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease
Ting Zhou, Ziwen Jin, Rilei Jiang, Weiwei Li
Frontiers in Pharmacology.2025;[Epub] CrossRef
Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation
Ao Liu, Mengting Huang, Yuwen Xi, Xiaoling Deng, Keshu Xu
Biomedicines.2025; 13(6): 1422. CrossRef
Gut microbiota in liver diseases: initiation, development and therapy
Jian-Xiu Yu, Jun Wu, Xin Chen, Su-gang Zang, Xue-bin Li, Li-Pei Wu, Shi-hai Xuan
Frontiers in Medicine.2025;[Epub] CrossRef
Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Yu-Jin Choi, Chang-Gue Son
Journal of Korean Medicine.2025; 46(2): 40. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives
Wenchu Qian, Ling He, Chenxue Fu, Tiantian Zeng, Hanyu Wang, Haifang Li
Exploration of Digestive Diseases.2025;[Epub] CrossRef
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD
Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu
ImmunoTargets and Therapy.2025; Volume 14: 719. CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
Gut and Liver.2025; 19(4): 479. CrossRef
Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease
Wenhao Wu, Zebin Hou
Frontiers in Immunology.2025;[Epub] CrossRef
Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease
Luis A. Rodríguez-Rojas, Leticia Bucio-Ortiz, Verónica Souza-Arroyo, María Concepción Gutiérrez-Ruiz, Luis E. Gómez-Quiroz, Roxana U. Miranda-Labra
Exploration of Digestive Diseases.2025;[Epub] CrossRef
Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies
Said A Al-Busafi, Ahmed Alwassief, Ali Madian, Hassan Atalla, Mohamed Alboraie, Ashraf Elbahrawy, Mohammed Eslam
World Journal of Hepatology.2025;[Epub] CrossRef
Present and Future Perspectives in the Treatment of Liver Fibrosis
Lucia Cerrito, Linda Galasso, Jacopo Iaccarino, Alessandro Pizzi, Fabrizio Termite, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
Pharmaceuticals.2025; 18(9): 1321. CrossRef
Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway
Jianping Zhu, Yuzhen Chen, Yidi Han, Ji Li, Fahrul Nurkolis
PLOS One.2025; 20(9): e0331303. CrossRef
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman
International Journal of Molecular Sciences.2025; 26(18): 8977. CrossRef
Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis
Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk
Probiotics and Antimicrobial Proteins.2025;[Epub] CrossRef
Impact of non-alcoholic hepatic steatosis on prognosis and clinical outcomes in gastric cancer patients undergoing laparoscopic distal gastrectomy
Yi-Fan Zou, Yi-Gang Zhang, Zi-Chu Zhao, Zheng Li, Hong-Da Liu, Qing-Ya Li, Ze-Tian Chen, Cheng-Jun Zhu, Hai-Tao Liu, Ji-Wei Wang, Feng-Yuan Li, Lin-Jun Wang, Dian-Cai Zhang, Li Yang, Hao Xu, Ze-Kuan Xu, Sen Wang
World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Recent research advances in RNA m5C methylation modification in liver diseases
Wenjuan Chen, Lifan Zhang, Xinyu Gu, Yafeng Liu, Shujun Zhang, Xinjun Hu, Penghui Li
Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis
Haifeng Wang, Songlin Liu, Yonggang Chen, Weiwei Fang, Ying Cheng, Zhigang Zhang, Haiming Hu, Baifei Hu, Hongtao Liu
Phytomedicine.2025; 148: 157404. CrossRef
Harnessing Gut Microbiome–Brain–Liver Crosstalk: Novel Therapeutic Strategies for Metabolic Dysfunction‐Associated Steatotic Liver Disease
Xingtao Zhao, Ruolan Li, Jingdong Zhao, Ruiqi Sun, Shuo Zhang, Qiong Pan, Hongyan Lu, Jin Chai
Medicine Bulletin.2025;[Epub] CrossRef
Sarcopenia and MASLD: novel insights and the future
Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng
Nature Reviews Endocrinology.2025;[Epub] CrossRef
Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites
Ping Li, Qingyuan Wu, Yuanhao Zhou, Xiaojuan Hu, Yan Tang, Yuanyuan Wang, Weijiao Fan, Yiyi Shan, Kexin Yu, Jie Wang, Shibing Wang, Xiao Ye, Huiyu Liu, Xiaozhou Mou
Nano Research.2025; 18(12): 94907986. CrossRef
Perturbed microbial ecology in pediatric systemic lupus erythematosus: Evidence from the gut microbiome and serum metabolome
Bo Li, Tao Ma, Yanjun Jia, Chunfeng Mou, Meng Zeng, Jie Yu, Lin Zou, Xiaoqiang Li, Han Wang
Genes & Diseases.2025; : 101932. CrossRef

10,834 View
428 Download
23 Web of Science
Crossref

Steatotic liver disease

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis: Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen; Clin Mol Hepatol 2025;31(1):227-239.
Published online November 14, 2024; DOI: https://doi.org/10.3350/cmh.2024.0564

Background/Aims
With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the USA. Therefore, we aimed to compare the long-term outcomes of patients with MASLD and cirrhosis with and without bariatric surgery.
Methods
Patients were retrospectively identified from the California Department of Healthcare Access and Information database, 2005 to 2019, for a population-based cohort study. Propensity score matching (PSM) was used to balance background risks between patients with cirrhosis who underwent bariatric surgery and those who did not. Overall, liver-related and non-liver-related mortality were analyzed.
Results
Of 91,708 eligible patients with MASLD and cirrhosis, PSM yielded 2,107 patients who underwent bariatric surgery and 8,428 non-bariatric controls. Compared to matched controls, patients who underwent bariatric surgery had lower 5-year overall (24.9% vs. 37.1%; p<0.0001), liver-related (3.3% vs. 14%; p<0.0001), and non-liver-related mortality (22.3% vs. 26.9%; p=0.046). In multivariable analysis, bariatric surgery was associated with decreased overall mortality (adjusted hazard ratio [aHR]=0.63; p<0.0001), liver-related (aHR=0.24; p<0.0001), and non-liverrelated (aHR=0.81; p=0.0026) mortality. However, only laparoscopic surgeries were associated with lower overall mortality (aHR=0.39; p<0.0001) whereas open surgeries were associated with higher overall mortality (aHR=1.24; p=0.022).
Conclusions
Patients with MASLD and cirrhosis who underwent bariatric surgery, specifically laparoscopic approaches, had significantly lower mortality risk than non-surgical counterparts.

Citations

Citations to this article as recorded by

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen
Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622. CrossRef
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic live
Jing Zeng, Jian-Gao Fan
Clinical and Molecular Hepatology.2025; 31(2): 610. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Wei Wang, Yating Xie, Ailei Xu
Clinical and Molecular Hepatology.2025; 31(2): e143. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho
Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen
Clinical and Molecular Hepatology.2025; 31(2): e173. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Jing Zeng, Jian-Gao Fan
Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou
Clinical and Molecular Hepatology.2025; 31(3): e252. CrossRef
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018
Yanshan Yi, Li Yang
Frontiers in Nutrition.2025;[Epub] CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai
Clinical and Molecular Hepatology.2025; 31(3): e247. CrossRef
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis
Pandora Fonseca, Leonardo Pereira, João Gabriel Braga, Giovanna Macanhã Scremin, Luísa de Araujo, Julia Alves, Gabriel de França, Pedro Bregion, Rafael Rego, Maria Farias, Victor Ivano
Obesity Surgery.2025; 35(10): 4246. CrossRef
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review
Janna Vanessa Diaz Torres, Vanessa Rocío Villanueva Guerrero, Jennifer Patricia Vargas Gómez, Fredy Javier Pacheco Miranda, Lorena Rocío Orozco Álvarez, Joseph David León Insignares, Marian Mares, Héctor Mario Rodríguez Ortiz, Evelyn Mendoza-Torres
Metabolic Syndrome and Related Disorders.2025; 23(10): 427. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications
Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas
Biomedicines.2025; 13(10): 2437. CrossRef

5,963 View
178 Download
10 Web of Science
Crossref

Steatotic liver disease

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”: Myeung Gi Choi, Na Young Lee, Ja Hyun Koo; Clin Mol Hepatol 2025;31(2):592-595.
Published online November 6, 2024; DOI: https://doi.org/10.3350/cmh.2024.0971

PDF

Citations

Citations to this article as recorded by

Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef

6,099 View
117 Download
1 Web of Science
Crossref

Steatotic liver disease

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”: Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li; Clin Mol Hepatol 2025;31(2):e145-e148.
Published online October 29, 2024; DOI: https://doi.org/10.3350/cmh.2024.0921

6,260 View
93 Download

Steatotic liver disease

Bioactive metabolites: A clue to the link between MASLD and CKD?: Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun; Clin Mol Hepatol 2025;31(1):56-73.
Published online October 21, 2024; DOI: https://doi.org/10.3350/cmh.2024.0782

Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.

Citations

Citations to this article as recorded by

Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges
Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease?
Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou
Frontiers in Nutrition.2025;[Epub] CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
Nutrients.2025; 17(13): 2211. CrossRef
Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism
Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong
Journal of Chromatography B.2025; 1267: 124784. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano
Exploration of Medicine.2025;[Epub] CrossRef
Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice
Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park
Journal of Agricultural and Food Chemistry.2025;[Epub] CrossRef

7,152 View
230 Download
5 Web of Science
Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”: Young Eun Chon, Jung Hwan Yu, Seung Up Kim; Clin Mol Hepatol 2025;31(1):e61-e63.
Published online October 15, 2024; DOI: https://doi.org/10.3350/cmh.2024.0878

PDF

4,779 View
39 Download

Steatotic liver disease

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”: Won Sohn; Clin Mol Hepatol 2025;31(1):277-280.
Published online October 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0823

PDF

Citations

Citations to this article as recorded by

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
Na Tian, Tie Xiao, Tianyi Xia, Hai‐Yang Yuan, Michael D. Shapiro, Gregory Y. H. Lip, Cheng‐Han Fanren, Li‐You Lian, Chen‐Xiao Huang, Yi‐Xuan Wei, Giovanni Targher, Christopher D. Byrne, Cheng‐Lv Hong, Shenghong Ju, Ming‐Hua Zheng
Alimentary Pharmacology & Therapeutics.2026; 63(1): 70. CrossRef
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy
Young Eun Chon, Jung Hwan Yu, Seung Up Kim
Clinical and Molecular Hepatology.2025; 31(1): e61. CrossRef
Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD
Aleksandra Bołdys, Maciej Borówka, Łukasz Bułdak, Bogusław Okopień
Metabolites.2025; 15(8): 510. CrossRef

5,832 View
53 Download
3 Web of Science
Crossref

Steatotic liver disease

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination: Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li; Clin Mol Hepatol 2025;31(1):147-165.
Published online October 2, 2024; DOI: https://doi.org/10.3350/cmh.2024.0478

Background/Aims
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma, but its role in MASLD remains unexplored. Therefore, the aim of this study was to reveal the effects and underlying mechanisms of USP29 in MASLD progression.
Methods
USP29 expression was assessed in liver samples from MASLD patients and mice. The role and molecular mechanism of USP29 in MASLD were assessed in high-fat diet-fed and high-fat/high-cholesterol diet-fed mice and palmitic acid and oleic acid treated hepatocytes.
Results
USP29 protein levels were significantly reduced in mice and humans with MASLD. Hepatic steatosis, inflammation and fibrosis were significantly exacerbated by USP29 deletion and relieved by USP29 overexpression. Mechanistically, USP29 significantly activated the expression of genes related to fatty acid β-oxidation (FAO) under metabolic stimulation, directly interacted with long-chain acyl-CoA synthase 5 (ACSL5) and repressed ACSL5 degradation by increasing ACSL5 K48-linked deubiquitination. Moreover, the effect of USP29 on hepatocyte lipid accumulation and MASLD was dependent on ACSL5.
Conclusions
USP29 functions as a novel negative regulator of MASLD by stabilizing ACSL5 to promote FAO. The activation of the USP29-ACSL5 axis may represent a potential therapeutic strategy for MASLD.

Citations

Citations to this article as recorded by

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
Jeysson E. Mejía-Guzmán, Ramón A. Belmont-Hernández, Norberto C. Chávez-Tapia, Misael Uribe, Natalia Nuño-Lámbarri
International Journal of Molecular Sciences.2025; 26(7): 2959. CrossRef
Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”
Myeung Gi Choi, Na Young Lee, Ja Hyun Koo
Clinical and Molecular Hepatology.2025; 31(2): 592. CrossRef
Association Between Visceral Adiposity and the Prediction of Hepatic Steatosis and Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Renata Bende, Darius Heredea, Iulia Rațiu, Ioan Sporea, Mirela Dănilă, Roxana Șirli, Alina Popescu, Felix Bende
Journal of Clinical Medicine.2025; 14(10): 3405. CrossRef
Alisol B ameliorated metabolic dysfunction-associated steatotic liver disease via regulating purine metabolism and restoring the gut microbiota disorders
Lin Yiyou, Zhang Congcong, Ren Guilin, Qiu Jiannan, Fu Yilong, Liu Fucai, Liu Qingsheng, Yu Zhiling, Chen Lin, Dou Xiaobing
Phytomedicine.2025; 145: 156992. CrossRef
ELAVL1-mediated USP29 mRNA degradation activates TAK1 driving M1 microglial polarization and neural stem cell differentiation dysregulation in spinal cord injury
Chunhe Sha, Feng Pan, Xiaodong Liu, Zhiqing Wang, Guohui Liu, Kai Huang
Cell Death Discovery.2025;[Epub] CrossRef
Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice
Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Ichimura-Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsu
Antioxidants.2025; 14(7): 891. CrossRef
Ubiquitination and ubiquitin-like modifications in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications
Hyunjin Rho, Uijin Kim, Jaewhan Song
BMB Reports.2025; 58(9): 371. CrossRef
USP2 promotes metabolic dysfunction-associated steatotic liver disease progression via stabilization of PPARγ
Hao Luo, Chujiao Zhu, Yingying Wang, Yidong Dai, Peng Hao, Haiyan Cai, Wenhui Bai, Zhenge Zhang, Jiale Wan, Youping Zhang, Yun Sun, Ziwei Zhang, Yunzhao Wu, Yuanhui Zhai, Wenxuan Wu, Hu Lei, Hanzhang Xu, Ming He, Yingli Wu
Cell Death & Differentiation.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis
Wei Li, Tong Liu, Tianhua Wu, Ting Cai, Fen Wang, Minglin Zhang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(6): 189492. CrossRef
Deubiquitinases in liver diseases: from mechanisms to targeted therapy
Zhenge Zhang, Wanli Duan, Yixiang Wang, Peng Hao, Linlin Chen, Ziyi Hao, Ming He, Yingli Wu, Hao Luo
Science China Life Sciences.2025;[Epub] CrossRef

8,172 View
657 Download
12 Web of Science
Crossref

Artificial intelligence, epidemiology, methodology, or others

Roles of X-box binding protein 1 in liver pathogenesis: Jihoon Tak, Yun Seok Kim, Sang Geon Kim; Clin Mol Hepatol 2025;31(1):1-31.
Published online October 2, 2024; DOI: https://doi.org/10.3350/cmh.2024.0441

Abstract
PDF

The prevalence of drug-induced liver injury (DILI) and viral liver infections presents significant challenges in modern healthcare and contributes to considerable morbidity and mortality worldwide. Concurrently, metabolic dysfunctionassociated steatotic liver disease (MASLD) has emerged as a major public health concern, reflecting the increasing rates of obesity and leading to more severe complications such as fibrosis and hepatocellular carcinoma. X-box binding protein 1 (XBP1) is a distinct transcription factor with a basic-region leucine zipper structure, whose activity is regulated by alternative splicing in response to disruptions in endoplasmic reticulum (ER) homeostasis and the unfolded protein response (UPR) activation. XBP1 interacts with a key signaling component of the highly conserved UPR and is critical in determining cell fate when responding to ER stress in liver diseases. This review aims to elucidate the emerging roles and molecular mechanisms of XBP1 in liver pathogenesis, focusing on its involvement in DILI, viral liver infections, MASLD, fibrosis/cirrhosis, and liver cancer. Understanding the multifaceted functions of XBP1 in these liver diseases offers insights into potential therapeutic strategies to restore ER homeostasis and mitigate liver damage.

Citations

Citations to this article as recorded by

Association between estimated glucose disposal rate and the risk of MAFLD in American adults: a cross-sectional study
Yuhang Zhou, Bang Wang, Miaoxin Wu, Han Hong, Gaochao Li, Minhui Xu
Scientific Reports.2025;[Epub] CrossRef
The Cardiohepatic Axis in Metabolic Disease
Andrew Hakeem, Jop van Berlo, Xavier S. Revelo
JACC: Basic to Translational Science.2025; 10(7): 101309. CrossRef
Beyond ER Stress: The Pleiotropic Roles of XBP1 in Development and Regeneration
Delan Huang, Fan Gu, Jingzhi Ma, Zhi Chen
Biomedicines.2025; 13(11): 2663. CrossRef
Association between estimated glucose disposal rate and metabolic-associated fatty liver disease among US adults: A cross-sectional study
Rong He, Kecen Zhao
Medicine.2025; 104(44): e45652. CrossRef
Inositol-requiring enzyme 1 alpha is essential for dentinogenesis
Qian Xu, Tian Liang, Jiahe Li, Suzhen Wang, Hua Zhang, Julie Hollien, Takao Iwawaki, Chunlin Qin, Yongbo Lu
Frontiers in Physiology.2025;[Epub] CrossRef

8,887 View
212 Download
4 Web of Science
Crossref

Artificial intelligence, epidemiology, methodology, or others

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”: Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan; Clin Mol Hepatol 2024;30(4):1039-1041.
Published online September 24, 2024; DOI: https://doi.org/10.3350/cmh.2024.0801

PDF

4,737 View
38 Download

Steatotic liver disease

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”: Yangyue Zhang, Vincent Wai-Sun Wong; Clin Mol Hepatol 2025;31(1):264-267.
Published online September 20, 2024; DOI: https://doi.org/10.3350/cmh.2024.0766

PDF

Citations

Citations to this article as recorded by

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analys
Jung Hwan Yu, Seung Up Kim
Clinical and Molecular Hepatology.2025; 31(1): e52. CrossRef
Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography
Ernesto Maddaloni, Marta Zerunian, Vincenzo Cardinale, Annalisa Zurru, Rocco Amendolara, Daniela Luverà, Renata Risi, Luca D’Onofrio, Benedetta Masci, Francesco Covotta, Damiano Caruso, Domenico Alvaro, Andrea Laghi, Raffaella Buzzetti
Diabetes Research and Clinical Practice.2025; 229: 112465. CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef

7,613 View
68 Download
2 Web of Science
Crossref

Steatotic liver disease

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes: Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen; Clin Mol Hepatol 2025;31(1):e35-e38.
Published online September 20, 2024; DOI: https://doi.org/10.3350/cmh.2024.0719

PDF

Citations

Citations to this article as recorded by

Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality
Mahsa Abbaszadeh, Farhad Hosseinpanah, Maryam Tohidi, Sahar Karimpour Reyhan, Maryam Mahdavi, Majid Valizadeh
Endocrinology, Diabetes & Metabolism.2025;[Epub] CrossRef

4,851 View
86 Download
1 Web of Science
Crossref

Steatotic liver disease

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”: Baokai Sun, Likun Zhuang; Clin Mol Hepatol 2025;31(1):e67-e69.
Published online September 10, 2024; DOI: https://doi.org/10.3350/cmh.2024.0744

PDF

3,900 View
91 Download

Steatotic liver disease

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”: Andrea Caddeo, Rosellina M. Mancina; Clin Mol Hepatol 2025;31(1):293-296.
Published online August 27, 2024; DOI: https://doi.org/10.3350/cmh.2024.0703

PDF

Citations

Citations to this article as recorded by

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
The correlation between the polymorphism of lysolecithin acyltransferase (MBOAT7) rs641738 and liver fibrosis
Yuxia Yang, Xiang Chen, Huiqin Zhang, Gang Yang, Xiaoyun Zhu, Xiujing Si, Feilong Chen, Yan Zhao, Feng Jin, Juanjuan Lu
Personalized Medicine.2025; 22(2): 113. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho
Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef

5,111 View
120 Download
Crossref

Steatotic liver disease

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality: Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed; Clin Mol Hepatol 2024;30(4):982-986.
Published online August 27, 2024; DOI: https://doi.org/10.3350/cmh.2024.0691

PDF

Citations

Citations to this article as recorded by

Increased MASH-associated liver cancer in younger demographics
Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D
Hepatology Communications.2025;[Epub] CrossRef

4,274 View
71 Download
1 Web of Science
Crossref

Steatotic liver disease

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD: Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang; Clin Mol Hepatol 2024;30(4):863-882.
Published online July 26, 2024; DOI: https://doi.org/10.3350/cmh.2024.0268

Backgrounds/Aims
Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood.
Methods
The Tm6sf2^167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2^167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC).
Results
The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFD-induced Tm6sf2^167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice.
Conclusions
The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.

Citations

Citations to this article as recorded by

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Andrea Caddeo, Rosellina M. Mancina
Clinical and Molecular Hepatology.2025; 31(1): 293. CrossRef
Causal roles of immune cells and metabolites in chronic pancreatitis: a mendelian randomization study
Chao Zhang, Tao Yang, Yuan Yu, Qian Jia, Wan-Meng Xiao, Sha Liu, Ze-Hui Yu, Cheng-Li Wen, Yan Wei, Hao Li, Mu-Han Lü
Hereditas.2025;[Epub] CrossRef
Effects of polyphenols on non-alcoholic fatty liver disease: a case study of resveratrol
Ying Zhao, Jiali Ren, Weisan Chen, Xinchen Gao, Hongjian Yu, Xiankuan Li, Yanchao Zheng, Jinlong Yang
Food & Function.2025; 16(8): 2926. CrossRef
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina
American Journal of Physiology-Cell Physiology.2025; 328(5): C1637. CrossRef
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement
Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(10): 13647. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years
Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim
Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef

6,977 View
322 Download
7 Web of Science
Crossref

Steatotic liver disease

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”: Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan; Clin Mol Hepatol 2024;30(4):649-652.
Published online July 23, 2024; DOI: https://doi.org/10.3350/cmh.2024.0558

PDF

Citations

Citations to this article as recorded by

AMPK Activation and Lipid Homeostasis Regulation in MASLD: Investigating the Hepatoprotective and Anti‐Inflammatory Effects of Meta‐Capridin Medium‐Chain Triglycerides
Alireza Doagoo, Sajad Ehtiati, Reza Ataei kachouei, Seyyed Hossein Khatami, Shima Rajaei, Maral Jalilzadeh, Nastaran Hamed, Fatemeh Namvarjah, Reyhane Ahmadzade, Marjan Ajami, Farzaneh Salmani, Somayeh Mahmoodi Baram, Mitra Rezaei, Majid Sirati-Sabet, Hoj
Journal of Food Biochemistry.2025;[Epub] CrossRef
Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study
Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai
European Journal of Pharmacology.2025; 1005: 178088. CrossRef
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim
Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef

5,200 View
118 Download
6 Web of Science
Crossref

Steatotic liver disease

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”: Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li; Clin Mol Hepatol 2024;30(4):1019-1022.
Published online July 8, 2024; DOI: https://doi.org/10.3350/cmh.2024.0471

PDF

Citations

Citations to this article as recorded by

Single‑cell RNA sequencing analysis of intrahepatic cholangiocarcinoma reveals SPP1 facilitates disease progression via interaction with CD4+ T cells
Xian Lin, Huanyan Peng, Ke Liu, Wenqi Chen, Ximing Shao, Chun Ning, Hongchang Li, Dongye Yang
Oncology Letters.2025; 30(2): 1. CrossRef

4,647 View
72 Download
Crossref

Steatotic liver disease

Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”: So Jung Kim, Jeongeun Hyun; Clin Mol Hepatol 2024;30(4):709-713.
Published online June 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0412

PDF

Citations

Citations to this article as recorded by

Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions
Huici Zhang, Xiaoyu Zhang, Xijun Ma, Xuan Wang
Pharmacological Reports.2025; 77(1): 72. CrossRef
Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools
Sherien M. Bakry, Riham A. El-Shiekh, Shymaa Hatem, Asmaa A. Mandour, Ahmed M. El-Dessouki, Abeer Bishr, Heba Elosaily, Ahmed F. Mohamed, Shaza M. Elhusseiny
Future Journal of Pharmaceutical Sciences.2025;[Epub] CrossRef
Negative Correlation Between Secreted Phosphoprotein 1 and the Treg/Th17 Ratio in Non-Valvular Atrial Fibrillation
Chao-Jun Yang, Bo Fu, Yi-Fan Huang, Jing-Yi Wu, Zhi-Xing Fan, Ya-Hui Li
Reviews in Cardiovascular Medicine.2025;[Epub] CrossRef
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Clinical and Molecular Hepatology.2024; 30(4): 1019. CrossRef

4,729 View
92 Download
3 Web of Science
Crossref

Steatotic liver disease

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease: Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li; Clin Mol Hepatol 2024;30(3):449-467.
Published online April 16, 2024; DOI: https://doi.org/10.3350/cmh.2024.0047

Background/Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become an increasingly important health challenge, with a substantial rise linked to changing lifestyles and global obesity. Ursolic acid, a natural pentacyclic triterpenoid, has been explored for its potential therapeutic effects. Given its multifunctional bioactive properties, this research further revealed the pharmacological mechanisms of ursolic acid on MASLD.
Methods
Drug target chips and bioinformatics analysis were combined in this study to explore the potential therapeutic effects of ursolic acid on MASLD. Molecular docking simulations, surface plasmon resonance analyses, pull-down experiments, and co-immunoprecipitation assays were used to verify the direct interactions. Gene knockdown mice were generated, and high-fat diets were used to validate drug efficacy. Furthermore, initial CD4⁺ T cells were isolated and stimulated to demonstrate our findings.
Results
In this study, the multifunctional extracellular matrix phosphorylated glycoprotein secreted phosphoprotein 1 (SPP1) was investigated, highlighting its capability to induce Th17 cell differentiation, amplifying inflammatory cascades, and subsequently promoting the evolution of MASLD. In addition, this study revealed that in addition to the canonical TGF-β/IL-6 cytokine pathway, SPP1 can directly interact with ITGB1 and CD44, orchestrating Th17 cell differentiation via their joint downstream ERK signaling pathway. Remarkably, ursolic acid intervention notably suppressed the protein activity of SPP1, suggesting a promising avenue for ameliorating the immunoinflammatory trajectory in MASLD progression.
Conclusions
Ursolic acid could improve immune inflammation in MASLD by modulating SPP1-mediated Th17 cell differentiation via the ERK signaling pathway, which is orchestrated jointly by ITGB1 and CD44, emerging as a linchpin in this molecular cascade.

Citations

Citations to this article as recorded by

The association between immunoinflammatory biomarkers NLR, PLR, LMR and nonalcoholic fatty liver disease: a systematic review and meta-analysis
Yunyi Yang, Xiaoli He, Shufa Tan, Xiaoxiao Qu, Weijin Huang, Jiayuan Cai, Jiawen You, Xinyi Fu, Yanming He, Hongjie Yang
Clinical and Experimental Medicine.2025;[Epub] CrossRef
Actichinone, a new ursane triterpenoid from Actinidia chinensis roots, ameliorates NAFLD via the AMPK and NF-κB pathways
Xinhua Li, Yuanlong Zhang, Leiqing Chen, Xiao Xu, Xiaohong Ma, Shuying Lou, Ziqiang Zou, Chenjing Wang, Bing Jiang, Yunrui Cai, Yu Qi, Yiyuan Xi, Min Zhao, Pengcheng Yan
European Journal of Pharmacology.2025; 990: 177276. CrossRef
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef
Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools
Sherien M. Bakry, Riham A. El-Shiekh, Shymaa Hatem, Asmaa A. Mandour, Ahmed M. El-Dessouki, Abeer Bishr, Heba Elosaily, Ahmed F. Mohamed, Shaza M. Elhusseiny
Future Journal of Pharmaceutical Sciences.2025;[Epub] CrossRef
Mechanistic study of a triterpenoid-enriched fraction derived from Cynomorium songaricum against NAFLD: An integrative elucidation
Zhihao Liu, Qixiang Shang, Juanjuan Cheng, Quanrun He, Yining Liu, Haimeng Li, Daozheng Fang, Xinyue Li, Yong Zhu, Jianping Chen, Jihang Chen
Phytomedicine.2025; 142: 156782. CrossRef
Camellia Japonica Radix modulates gut microbiota and 9(S)-HpODE-mediated ferroptosis to alleviate oxidative stress against MASLD
Simin Gu, Chong Chen, Junmin Wang, Yanping Wang, Lina Zhao, Zhekun Xiong, Hui Zhang, Taoying Deng, Qihui Pan, Yiyuan Zheng, Yong Li
Phytomedicine.2025; 143: 156806. CrossRef
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke
Cellular & Molecular Immunology.2025; 22(10): 1159. CrossRef
Ursolic Acid Alleviates DSS-Induced Colitis and Associated Liver Damage by Restoring Treg/Th17 Balance and Modulating Gut Microbiota and Its Histidine Metabolism
Man Zhao, Mengqi Liu, Fengyang Wu, Chong Li, Shudong Liu, Xinyu Yang, Zhonghua Wei, Baojiang Chen, Shuaijuan Han
Journal of Agricultural and Food Chemistry.2025; 73(26): 16317. CrossRef
Identification of Schwann Cells in Human Intracranial Arteries: Potential Regulatory Role in Atherosclerotic Plaque Progression
Zijue Wang, Yangzhige He, Weizhuang Yuan, Yijun Xia, Manqiu Ding, Zhen Chen, Naili Wang, Chao Ma, Xiaoyue Wang, Yan Xu, Weihai Xu
Advanced Science.2025;[Epub] CrossRef
Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer
Chengquan Shen, Jing Liu, Ding Hu, Changxue Liu, Fei Xie, Yonghua Wang
Journal of Experimental & Clinical Cancer Research.2025;[Epub] CrossRef
ncRNA-mediated ITGB1 upregulation correlates with poor prognosis and tumor-immune infiltration in gastric cancer
Tianen Li, Wei Su, Zhiqiang Wang, Xiao Wang, Xiaoguang Ma, Rui Zhao
European Journal of Medical Research.2025;[Epub] CrossRef
Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation
Yijing Zhou, Chengli Lou, Xiuqin Xu, Bo Feng, Xiaoping Fan, Xiangjing Wang
Drug Design, Development and Therapy.2025; Volume 19: 6699. CrossRef
Therapeutic potential of plant-derived natural products against drug-induced liver injury
Yan Chen, Yu-Qi Mei, Lin Hou, Ke-Jian Li
Frontiers in Pharmacology.2025;[Epub] CrossRef
Cell membrane-camouflaged nanoparticles boost combined chemo/immunotherapy for gastric cancer
Xiaohua Dong, Miao Yu, Yuanyuan Zhang, Liuli Wang, Lihui Zhu, Da Wang, Xiaojun Yang, Mingzhen Zhang, Xiaoliang Zheng, Hui Cai
Nano Research.2025; 18(10): 94907897. CrossRef
Antihyperlipidemic Effect of Flavonoids and Saponins from Pyracantha fortuneana Fruits on L02 Cells and Caenorhabditis elegans
Yunfang Hao, Yinhong Wang, Kexin Hao, Yimeng Li, Longmei Geng, Liang Zhu, Jianguo Jiang
Foods.2025; 14(20): 3499. CrossRef
Paeoniflorin attenuates hepatic ischemia-reperfusion injury by modulating Tmem176b+ macrophages polarization
Xiao Tang, Yawen Tan, Fengqiang Gao, Zhoucheng Wang, Xinyu Ye, Xun Qiu, Zijian Lou, Xinyu Yang, Jun Chen, Hao Xu, Jian Chen, Xiao Xu, Kai Wang
International Immunopharmacology.2025; 167: 115657. CrossRef
Osthol ameliorates obesity-associated lipid metabolic disorders by inhibiting ADRA1D-dependent Th17 cell differentiation
Pei Li, Chao He, Chao Wu, Xinbo Zhou, Yiran Ma, Qi Deng
Scientific Reports.2025;[Epub] CrossRef
Mapping the genetic–transcriptional landscape of thyroid irAEs in sintilimab therapy: toward biomarker-guided immunotoxicity prediction
Wei Chen, Mingyu Zhang, Taifeng Li, Bing Shang, Haishuai Su, Yafei Shi, Yutao Liu, Feng Yu, Guohui Li
Frontiers in Immunology.2025;[Epub] CrossRef
The relationship between tobacco and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis of observational studies
Jianxiang Jin, Yuping Zhang, Yiping Huang
Frontiers in Medicine.2025;[Epub] CrossRef
Deconstruction of tophi and synovium defines SPP1+ macrophages involved in extracellular matrix remodelling in gout
Hanlin Xu, Zhechen Liu, Xiaofeng Zhou, Xiaoxi Ji, Xingwang Liu, Xiaoxia Zhu, Liwei Lu, Nicola Dalbeth, Rui He, Yinghui Hua
Annals of the Rheumatic Diseases.2025; 84(12): 2088. CrossRef
Negative Correlation Between Secreted Phosphoprotein 1 and the Treg/Th17 Ratio in Non-Valvular Atrial Fibrillation
Chao-Jun Yang, Bo Fu, Yi-Fan Huang, Jing-Yi Wu, Zhi-Xing Fan, Ya-Hui Li
Reviews in Cardiovascular Medicine.2025;[Epub] CrossRef
Research Progress and Prospects of Saponins in the Treatment of NAFLD: A Narrative Review
Shuang Xue, Qiao Wang, Xuan Guo, Xingtong Chen, Yunyue Zhou, Jinbiao Yang, Yukun Zhang, Wenying Niu
Molecules.2025; 30(21): 4247. CrossRef
Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD
Huihui Zhao, Weili Wang, Pengchao Zhu, Zhaohong Shi
Frontiers in Immunology.2025;[Epub] CrossRef
Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression
Changpeng Hu, Ming Qin, Wenjing Lai, Huyue Zhou, Chengsha Yuan, Yafeng Liu, Yue Dai, Mengmeng Yang, Min Hu, Xuan Wang, Menglin Luo, Rong Zhang, Guobing Li
Journal for ImmunoTherapy of Cancer.2025; 13(11): e012586. CrossRef
Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols
Raissa Bulaty Tauil, Paula Takano Golono, Enzo Pereira de Lima, Ricardo de Alvares Goulart, Elen Landgraf Guiguer, Marcelo Dib Bechara, Claudia C. T. Nicolau, José Luiz Yanaguizawa Junior, Adriana M. R. Fiorini, Nahum Méndez-Sánchez, Ludovico Abenavoli, R
Pharmaceuticals.2024; 17(10): 1354. CrossRef
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Clinical and Molecular Hepatology.2024; 30(4): 1019. CrossRef
Complex Inhibitory Activity of Pentacyclic Triterpenoids against Cutaneous Melanoma In Vitro and In Vivo: A Literature Review and Reconstruction of Their Melanoma-Related Protein Interactome
Arseny D. Moralev, Marina A. Zenkova, Andrey V. Markov
ACS Pharmacology & Translational Science.2024; 7(11): 3358. CrossRef
Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against
So Jung Kim, Jeongeun Hyun
Clinical and Molecular Hepatology.2024; 30(4): 709. CrossRef
Deep Learning and Single‐Cell Sequencing Analyses Unveiling Key Molecular Features in the Progression of Carotid Atherosclerotic Plaque
Han Zhang, Yixian Wang, Mingyu Liu, Yao Qi, Shikai Shen, Qingwei Gang, Han Jiang, Yu Lun, Jian Zhang
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef

10,528 View
499 Download
29 Web of Science
Crossref

Steatotic liver disease

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia: Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi; Clin Mol Hepatol 2024;30(3):577-579.
Published online March 6, 2024; DOI: https://doi.org/10.3350/cmh.2024.0157

PDF

Citations

Citations to this article as recorded by

Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
Cells.2025; 14(6): 428. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1
Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li
Metabolism.2025; 168: 156242. CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3
Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki
Internal Medicine.2025; 64(9): 1296. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
JHEP Reports.2025; 7(9): 101477. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024)
Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech
Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Impact of Continuous Nutritional Counseling on Liver Function and Body Composition in Patients with MASLD/MASH
Shiho Asai, Naoto Kawabe, Akemi Ito, Teiji Kuzuya, Eizaburo Ohno, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yuka Ochi, Sayuri Miyaji, Sayaka Morisaki, Yoshiki Hirooka
Kanzo.2025; 66(6): 222. CrossRef
Serum Desmosterol Level Reflects Hepatic Inflammation Grade in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatotic Liver Disease
Takashi Omatsu, Masahiro Koseki, Kaori Ito, Ayami Saga, Hiroshi Sawabe, Katsunao Tanaka, Hiroyasu Inui, Takeshi Okada, Makoto Nishida, Hirokazu Takahashi, Shinichi Aishima, Yoshihiro Kamada, Hiroshi Yoshida, Yasushi Sakata
Journal of Atherosclerosis and Thrombosis.2025;[Epub] CrossRef
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities
Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad
JGH Open.2025;[Epub] CrossRef
Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk
Gut Microbes.2025;[Epub] CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto
JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication
Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi
Hepatology Research.2024; 54(8): 729. CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef

5,581 View
182 Download
16 Web of Science
Crossref

Steatotic liver disease

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences: Joo Hyun Oh, Dae Won Jun; Clin Mol Hepatol 2024;30(2):168-170.
Published online March 5, 2024; DOI: https://doi.org/10.3350/cmh.2024.0140

PDF

Citations

Citations to this article as recorded by

Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
BMC Gastroenterology.2025;[Epub] CrossRef
Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor
Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, Shalimar
Journal of Clinical and Experimental Hepatology.2025; 15(5): 102559. CrossRef
Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study
Xuan-Yu Wang, Qiong Lyu, Yang-Yang Zhang, Yue Su, Hongjie Zhao, Hui-Hui Shen, Ying-Yu Xie
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in metabolic dysfunction associated steatotic liver disease
Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
Scientific Reports.2025;[Epub] CrossRef
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez
PLOS One.2025; 20(7): e0327772. CrossRef
Steatotic liver disease: radiological and ultrasound point of view
Alexey V. Borsukov, Daria Yu. Shestakova
Consilium Medicum.2025; 27(5): 296. CrossRef
Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk
Gut Microbes.2025;[Epub] CrossRef
Resolution of Metabolic Dysfunction Improves Liver Health Among Chinese Children: Evidence From Two Prospective Cohorts
Lili Yang, Menglong Li, Min Zhao, Yifei Hu, Bo Xi
Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada
Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef

5,582 View
109 Download
9 Web of Science
Crossref

Steatotic liver disease

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi; Clin Mol Hepatol 2024;30(2):266-268.
Published online January 30, 2024; DOI: https://doi.org/10.3350/cmh.2024.0028

Citations

Citations to this article as recorded by

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
In-silico identification and experimental validation of shared genes and pathways to decipher the molecular links between COPD and MASLD
Anupama Dubey, Praveen Kumar, Tahseen Khan, Suneel Kateriya, Dinesh Mani Tripathi, Umesh C.S. Yadav
Computers in Biology and Medicine.2025; 194: 110532. CrossRef
Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction
Che-Hao Tseng, Bor-Yang Jou, Hsiao-Chin Shen, Hsiao-Yun Yeh, Shiao-Ya Hong, Yi-Hsuan Lin, Hung-Cheng Tsai, Tzu-Hao Li, Chien-Wei Su, Kun-Ta Chou, Diahn Warng Perng, Ying-Ying Yang, Ming-Chih Hou
BMJ Open Respiratory Research.2025; 12(1): e003352. CrossRef
Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults
Dayang Zheng, Xiang Liu, Wei Zeng, Wangyan Zhou, Chunxiang Zhou
Scientific Reports.2024;[Epub] CrossRef

5,147 View
75 Download
Crossref

Steatotic liver disease

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study: Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD); Clin Mol Hepatol 2024;30(2):225-234.
Published online January 24, 2024; DOI: https://doi.org/10.3350/cmh.2023.0515

Background/Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Methods
This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD.
Results
Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m² vs. 28.0 kg/m², P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4).
Conclusions
Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.

Citations

Citations to this article as recorded by

Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
Annals of Hepatology.2025; 30(1): 101750. CrossRef
Alcohol Intake and Cardiometabolic Risk Factors Are Independently Associated With a Higher AST/Platelet Ratio Index in Obese Males
Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Tsubasa Tsutsumi, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nakajima, Tomoari Kam
Liver International Communications.2025;[Epub] CrossRef
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
Cells.2025; 14(6): 428. CrossRef
Reducing complications of metabolic dysfunction–associated steatotic liver disease
Naohiro Wada, Michihiro Iwaki, Takashi Kobayashi, Atsushi Nakajima, Masato Yoneda
Expert Review of Gastroenterology & Hepatology.2025; 19(5): 577. CrossRef
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez
PLOS One.2025; 20(7): e0327772. CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study
Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae
Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Effects of laser acupuncture (stress-free therapy) on blood liver function indicators
Yoshihiro Kamada, Takunori Sato, Takaomi Kessoku, Yoshio Sumida, Masafumi Ono, Kenji Ryotokuji
Laser Therapy.2025;[Epub] CrossRef
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada
Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto
JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication
Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi
Hepatology Research.2024; 54(8): 729. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun
Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
Yeo-Wool Kang, Yang-Hyun Baek, Sang-Yi Moon
Diagnostics.2024; 14(22): 2517. CrossRef
Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease
Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim
Gut and Liver.2024; 18(6): 1048. CrossRef

9,885 View
277 Download
19 Web of Science
Crossref

Page Path

"Steatotic liver disease"

Article category

Keywords

Publication year

Article category

Keywords

Publication Year

Funded articles

"Steatotic liver disease"

Original Articles

Correspondences

Editorial

Review

Letter to the Editor

Original Article

Editorials

Original Article

Editorial

Original Articles

Review

Letters to the Editor

Special Issue

Steatotic liver disease

Editorial

Reply to Correspondence

Steatotic liver disease

Letter to the Editor

Correspondences

Steatotic liver disease

Steatotic liver disease

Steatotic liver disease

Editorial

Steatotic liver disease

Letter to the Editor

Hepatic neoplasm

Review

Steatotic liver disease

Original Article

Steatotic liver disease

Editorial

Steatotic liver disease

Letter to the Editor

Steatotic liver disease

Review

Steatotic liver disease

Correspondence

Liver fibrosis, cirrhosis, and portal hypertension

Editorial

Steatotic liver disease

Original Article

Steatotic liver disease

Review

Artificial intelligence, epidemiology, methodology, or others

Reply to Correspondence

Artificial intelligence, epidemiology, methodology, or others

Editorial

Steatotic liver disease

Letter to the Editor

Steatotic liver disease

Correspondence

Steatotic liver disease

Editorial

Steatotic liver disease

Letter to the Editor

Steatotic liver disease

Original Article

Steatotic liver disease

Editorial

Steatotic liver disease

Correspondence

Steatotic liver disease

Editorial

Steatotic liver disease

Original Article

Steatotic liver disease

Letter to the Editor

Steatotic liver disease

Editorial

Steatotic liver disease